title: Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer.
abstract: We evaluated the effects of bisphosphonate (BP) treatment in five patients with hormone-refractory prostate cancer (HRPC), experiencing bone pain from metastases to the bone, and assessed changes in serum prostate specific antigen (PSA) levels, bone pain, and quality of life (QOL). Treatment with incadronate disodium (10 mg) in saline was administered at 2-week intervals for a total of 6 times. Evaluation of the treatment included the incidence of adverse events, QOL, bone pain, pain scale, and blood analyses including tumor markers. BP treatment was generally well tolerated by all five patients. The effects of BP treatment on serum PSA values were evaluated as prominent response (PR), no change (NC) and progressive disease (PD) in one, two and two cases of PD, respectively. During BP treatment, serum type I procollagen values decreased in patients, but there was no large change in serum type I collagen values. Only one patient experienced increased pain; pain was well controlled in the others. The QOL evaluation by Short-Form 36 (SF-36), showed no change in scores during BP treatment except for general health. These results suggested that BP treatment is safe and feasible. It may be effective for the treatment of those HRPC patients with bone pain and may become one of the choices for treatment of HRPC.
authors.affiliation: Department of Urology, Chiba University Graduate School of Medicine.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ueda
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Suzuki
authors.forename: Koichiro
authors.initials: K
authors.lastname: Akakura
authors.forename: Masaharu
authors.initials: M
authors.lastname: Ishihara
authors.forename: Naoto
authors.initials: N
authors.lastname: Kamiya
authors.forename: Akira
authors.initials: A
authors.lastname: Komiya
authors.forename: Masaki
authors.initials: M
authors.lastname: Shimbo
authors.forename: Takahito
authors.initials: T
authors.lastname: Suyama
authors.forename: Shinichi
authors.initials: S
authors.lastname: Sakamoto
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Ichikawa
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D003907:Dexamethasone / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D010148:Intractable Pain / Q000188:drug therapy; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D011788:Quality of Life / Q000523:psychology*
chemical_list: D004164:Diphosphonates; D003907:Dexamethasone; D017430:Prostate-Specific Antigen